With EBV+ AIDS-DLBCL patients continuing to face poorer outcomes compared to EBV- AIDS-DLBCL patients despite antiretroviral therapy and advanced chemotherapeutic regimens [42,43], targeting ZC3H18 alongside EBNA1 (or STAT3) may offer greater benefit. The gene discussed is ZC3H18; the disease is diffuse large B-cell lymphoma.